复发/难治性弥漫大B细胞淋巴瘤的中西医治疗进展  

Progress on traditional Chinese and western medicine treatment of relapsed/refractory diffuse large B cell lymphoma

作　　者：司华炆 胡琦[1] SI Huawen;HU Qi(Department of Hematology,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai200071,China)

机构地区：[1]上海中医药大学附属市中医医院血液病科,上海200071

出　　处：《中国医药导报》2024年第29期92-97,共6页China Medical Herald

基　　金：上海市科学技术委员会资助项目(18401903900)。

摘　　要：弥漫大B细胞淋巴瘤(DLBCL)是起源于B细胞的恶性侵袭性淋巴瘤。尽管R-CHOP方案已明显改善患者预后,但仍有40%的患者出现耐药或在达到完全缓解后2年内复发,患者总生存时间明显缩短。探索新的治疗方法以提高复发/难治性患者的生存率迫在眉睫。近年来,肿瘤领域的分子免疫学药物开发迅猛发展,本文对蛋白酶体抑制剂、布鲁顿酪氨酸激酶抑制剂、组蛋白脱乙酰酶抑制剂等新型小分子靶向药物及嵌合抗原受体T细胞治疗等新兴疗法的临床研究进展进行综述,并总结现代中医论治淋巴瘤的理论和方法,以期为复发/难治性DLBCL患者制订精准个体化医学治疗提供新思路。Diffuse large B cell lymphoma(DLBCL)is a malignant aggressive lymphoma of B cell origin.Although R-CHOP scheme has significantly improved patient outcome,40%of patients develop resistance or relapse within two years of achieving complete response,and overall survival of patients are significantly reduced.It is urgent to explore new therapeutic approaches to improve survival rate of relapsed/refractory patients.In recent years,the development of molecular immunological drugs in the field of cancer has been rapidly developing.This article reviews clinical research progress of new small molecule targeted drugs such as proteasome inhibitors,Bruton tyrosine kinase inhibitors,histone deacetylase inhibitors,and emerging therapies such as chimeric antigen receptor T cell therapy.It also summarizes the theories and methods of modern traditional Chinese medicine for treating lymphoma,in order to provide new ideas for the development of precise personalized medical treatment for recurrent/refractory DLBCL patients.

关 键 词：复发/难治性弥漫大B细胞淋巴瘤 中西医结合 靶向药物 免疫疗法 

分 类 号：R733[医药卫生—肿瘤]